Chembio Diagnostics, Inc. (NASDAQ: CEMI) Stock Competitors & Peer Comparison
See CEMI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CEMI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CEMI | $0.46 | +0.22% | 16.7M | -0.63 | -$0.72 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.71% |
| TMO | $589.04 | +0.60% | 218.9B | 25.44 | $23.16 | +0.31% |
| DHR | $199.58 | -1.51% | 140.4B | 25.02 | $7.98 | +0.71% |
| NTRA | $311.69 | -0.79% | 44.6B | -236.13 | -$1.32 | N/A |
| IDXX | $553.32 | +1.32% | 43.6B | 38.91 | $14.22 | N/A |
| A | $148.44 | -0.01% | 41.9B | 25.55 | $5.81 | +0.68% |
| IQV | $240.03 | -0.50% | 39.5B | 19.79 | $12.13 | N/A |
| WAT | $401.25 | -1.59% | 30B | 29.33 | $13.68 | N/A |
| ILMN | $188.29 | -2.51% | 28.5B | 37.43 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
CEMI vs DHR-PB Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, CEMI's ROE is -0.89%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, CEMI is less volatile compared to DHR-PB. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
CEMI vs TMO Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, TMO has a market cap of 218.9B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while TMO trades at $589.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas TMO's P/E ratio is 25.44. In terms of profitability, CEMI's ROE is -0.89%, compared to TMO's ROE of +0.13%. Regarding short-term risk, CEMI is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
CEMI vs DHR Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, DHR has a market cap of 140.4B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while DHR trades at $199.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas DHR's P/E ratio is 25.02. In terms of profitability, CEMI's ROE is -0.89%, compared to DHR's ROE of +0.08%. Regarding short-term risk, CEMI is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
CEMI vs NTRA Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NTRA has a market cap of 44.6B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NTRA trades at $311.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NTRA's P/E ratio is -236.13. In terms of profitability, CEMI's ROE is -0.89%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, CEMI is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NTRA's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
CEMI vs IDXX Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, IDXX has a market cap of 43.6B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while IDXX trades at $553.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas IDXX's P/E ratio is 38.91. In terms of profitability, CEMI's ROE is -0.89%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, CEMI is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
CEMI vs A Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, A has a market cap of 41.9B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while A trades at $148.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas A's P/E ratio is 25.55. In terms of profitability, CEMI's ROE is -0.89%, compared to A's ROE of +0.21%. Regarding short-term risk, CEMI is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
CEMI vs IQV Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, IQV has a market cap of 39.5B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while IQV trades at $240.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas IQV's P/E ratio is 19.79. In terms of profitability, CEMI's ROE is -0.89%, compared to IQV's ROE of +0.22%. Regarding short-term risk, CEMI is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check IQV's competition here
Waters Corporation (NYSE: WAT)
CEMI vs WAT Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, WAT has a market cap of 30B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while WAT trades at $401.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas WAT's P/E ratio is 29.33. In terms of profitability, CEMI's ROE is -0.89%, compared to WAT's ROE of +0.02%. Regarding short-term risk, CEMI is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check WAT's competition here
Illumina, Inc. (NASDAQ: ILMN)
CEMI vs ILMN Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ILMN has a market cap of 28.5B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ILMN trades at $188.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ILMN's P/E ratio is 37.43. In terms of profitability, CEMI's ROE is -0.89%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, CEMI is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
CEMI vs MTD Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MTD has a market cap of 28.3B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MTD trades at $1,399.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MTD's P/E ratio is 32.17. In terms of profitability, CEMI's ROE is -0.89%, compared to MTD's ROE of -12.00%. Regarding short-term risk, CEMI is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
CEMI vs LH Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, LH has a market cap of 26.4B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while LH trades at $322.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas LH's P/E ratio is 19.12. In terms of profitability, CEMI's ROE is -0.89%, compared to LH's ROE of +0.12%. Regarding short-term risk, CEMI is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
CEMI vs DGX Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, DGX has a market cap of 26.1B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while DGX trades at $236.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas DGX's P/E ratio is 23.30. In terms of profitability, CEMI's ROE is -0.89%, compared to DGX's ROE of +0.14%. Regarding short-term risk, CEMI is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
CEMI vs GH Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, GH has a market cap of 21.5B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while GH trades at $160.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas GH's P/E ratio is -45.88. In terms of profitability, CEMI's ROE is -0.89%, compared to GH's ROE of +2.11%. Regarding short-term risk, CEMI is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
CEMI vs EXAS Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas EXAS's P/E ratio is -95.37. In terms of profitability, CEMI's ROE is -0.89%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, CEMI is similarly volatile compared to EXAS. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
CEMI vs ILMNV Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ILMNV's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to ILMNV's ROE of N/A. Regarding short-term risk, CEMI is similarly volatile compared to ILMNV. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
CEMI vs MEDP Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MEDP has a market cap of 16.5B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MEDP trades at $590.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MEDP's P/E ratio is 34.60. In terms of profitability, CEMI's ROE is -0.89%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, CEMI is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
CEMI vs PKI Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas PKI's P/E ratio is 41.45. In terms of profitability, CEMI's ROE is -0.89%, compared to PKI's ROE of +0.03%. Regarding short-term risk, CEMI is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
CEMI vs CRL Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CRL has a market cap of 13.4B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CRL trades at $279.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CRL's P/E ratio is 28.20. In terms of profitability, CEMI's ROE is -0.89%, compared to CRL's ROE of -0.08%. Regarding short-term risk, CEMI is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
CEMI vs ICLR Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ICLR has a market cap of 12.8B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ICLR trades at $167.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ICLR's P/E ratio is 13.63. In terms of profitability, CEMI's ROE is -0.89%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, CEMI is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check ICLR's competition here
Revvity, Inc. (NYSE: RVTY)
CEMI vs RVTY Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, RVTY has a market cap of 12.7B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while RVTY trades at $113.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas RVTY's P/E ratio is 21.26. In terms of profitability, CEMI's ROE is -0.89%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, CEMI is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check RVTY's competition here
Qiagen N.V. (NYSE: QGEN)
CEMI vs QGEN Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, QGEN has a market cap of 8.7B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while QGEN trades at $42.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas QGEN's P/E ratio is 17.50. In terms of profitability, CEMI's ROE is -0.89%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, CEMI is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check QGEN's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
CEMI vs TWST Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, TWST has a market cap of 7.2B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while TWST trades at $116.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas TWST's P/E ratio is -52.30. In terms of profitability, CEMI's ROE is -0.89%, compared to TWST's ROE of -0.30%. Regarding short-term risk, CEMI is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check TWST's competition here
RadNet, Inc. (NASDAQ: RDNT)
CEMI vs RDNT Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, RDNT has a market cap of 5.8B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while RDNT trades at $73.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas RDNT's P/E ratio is 160.50. In terms of profitability, CEMI's ROE is -0.89%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, CEMI is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
CEMI vs SHC Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while SHC trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas SHC's P/E ratio is 19.28. In terms of profitability, CEMI's ROE is -0.89%, compared to SHC's ROE of +0.27%. Regarding short-term risk, CEMI is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
CEMI vs SYNH Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas SYNH's P/E ratio is 61.40. In terms of profitability, CEMI's ROE is -0.89%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, CEMI is less volatile compared to SYNH. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check SYNH's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
CEMI vs BLLN Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BLLN has a market cap of 4.3B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BLLN trades at $87.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BLLN's P/E ratio is 134.16. In terms of profitability, CEMI's ROE is -0.89%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, CEMI is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BLLN's competition here
Veracyte, Inc. (NASDAQ: VCYT)
CEMI vs VCYT Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while VCYT trades at $40.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas VCYT's P/E ratio is 20.34. In terms of profitability, CEMI's ROE is -0.89%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, CEMI is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check VCYT's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
CEMI vs OLK Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas OLK's P/E ratio is -96.59. In terms of profitability, CEMI's ROE is -0.89%, compared to OLK's ROE of -0.07%. Regarding short-term risk, CEMI is less volatile compared to OLK. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check OLK's competition here
Neogen Corporation (NASDAQ: NEOG)
CEMI vs NEOG Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NEOG has a market cap of 2.5B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NEOG trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NEOG's P/E ratio is 41.32. In terms of profitability, CEMI's ROE is -0.89%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, CEMI is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NEOG's competition here
CareDx, Inc (NASDAQ: CDNA)
CEMI vs CDNA Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CDNA has a market cap of 2.4B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CDNA trades at $46.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CDNA's P/E ratio is 54.98. In terms of profitability, CEMI's ROE is -0.89%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, CEMI is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
CEMI vs PSNL Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, PSNL has a market cap of 1.5B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while PSNL trades at $13.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas PSNL's P/E ratio is -12.76. In terms of profitability, CEMI's ROE is -0.89%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, CEMI is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check PSNL's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
CEMI vs CSTL Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CSTL has a market cap of 886.9M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CSTL trades at $29.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CSTL's P/E ratio is -65.98. In terms of profitability, CEMI's ROE is -0.89%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, CEMI is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
CEMI vs GRALV Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas GRALV's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to GRALV's ROE of N/A. Regarding short-term risk, CEMI is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check GRALV's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
CEMI vs FLGT Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, FLGT has a market cap of 527.4M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while FLGT trades at $18.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas FLGT's P/E ratio is 1857.00. In terms of profitability, CEMI's ROE is -0.89%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, CEMI is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check FLGT's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
CEMI vs NEO Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NEO has a market cap of 408.6M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NEO trades at $15.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NEO's P/E ratio is 122.31. In terms of profitability, CEMI's ROE is -0.89%, compared to NEO's ROE of -0.06%. Regarding short-term risk, CEMI is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
CEMI vs CO Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CO's P/E ratio is 5.06. In terms of profitability, CEMI's ROE is -0.89%, compared to CO's ROE of +0.11%. Regarding short-term risk, CEMI is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check CO's competition here
Prenetics Global Limited (NASDAQ: PRE)
CEMI vs PRE Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, PRE has a market cap of 329.8M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while PRE trades at $19.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas PRE's P/E ratio is -9.42. In terms of profitability, CEMI's ROE is -0.89%, compared to PRE's ROE of -0.47%. Regarding short-term risk, CEMI is less volatile compared to PRE. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check PRE's competition here
Prenetics Global Limited (NASDAQ: PRENW)
CEMI vs PRENW Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, PRENW has a market cap of 310.6M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas PRENW's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to PRENW's ROE of -0.47%. Regarding short-term risk, CEMI is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check PRENW's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
CEMI vs FLDM Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas FLDM's P/E ratio is -4.74. In terms of profitability, CEMI's ROE is -0.89%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, CEMI is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check FLDM's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
CEMI vs MYGN Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MYGN has a market cap of 271.1M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MYGN trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MYGN's P/E ratio is -22.08. In terms of profitability, CEMI's ROE is -0.89%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, CEMI is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MYGN's competition here
Trinity Biotech plc (NASDAQ: TRIB)
CEMI vs TRIB Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, TRIB has a market cap of 241.2M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while TRIB trades at $12.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas TRIB's P/E ratio is -0.20. In terms of profitability, CEMI's ROE is -0.89%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, CEMI is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check TRIB's competition here
Biodesix, Inc. (NASDAQ: BDSX)
CEMI vs BDSX Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BDSX has a market cap of 189.3M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BDSX trades at $22.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BDSX's P/E ratio is -7.33. In terms of profitability, CEMI's ROE is -0.89%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, CEMI is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
CEMI vs XGN Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, XGN has a market cap of 159.2M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while XGN trades at $6.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas XGN's P/E ratio is -9.55. In terms of profitability, CEMI's ROE is -0.89%, compared to XGN's ROE of -1.22%. Regarding short-term risk, CEMI is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
CEMI vs IMDX Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, IMDX has a market cap of 138.2M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while IMDX trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas IMDX's P/E ratio is -3.60. In terms of profitability, CEMI's ROE is -0.89%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, CEMI is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
CEMI vs GTH Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas GTH's P/E ratio is -1.11. In terms of profitability, CEMI's ROE is -0.89%, compared to GTH's ROE of -1.01%. Regarding short-term risk, CEMI is less volatile compared to GTH. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
CEMI vs GENE Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas GENE's P/E ratio is -38.25. In terms of profitability, CEMI's ROE is -0.89%, compared to GENE's ROE of -1.85%. Regarding short-term risk, CEMI is similarly volatile compared to GENE. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
CEMI vs SERA Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, SERA has a market cap of 73.7M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while SERA trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas SERA's P/E ratio is -2.97. In terms of profitability, CEMI's ROE is -0.89%, compared to SERA's ROE of -0.47%. Regarding short-term risk, CEMI is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check SERA's competition here
Atlantic International Corp. (NASDAQ: ATLN)
CEMI vs ATLN Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CEMI's ROE is -0.89%, compared to ATLN's ROE of +14.94%. Regarding short-term risk, CEMI is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check ATLN's competition here
DarioHealth Corp. (NASDAQ: DRIO)
CEMI vs DRIO Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, DRIO has a market cap of 52.5M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while DRIO trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas DRIO's P/E ratio is -1.23. In terms of profitability, CEMI's ROE is -0.89%, compared to DRIO's ROE of +1.04%. Regarding short-term risk, CEMI is less volatile compared to DRIO. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check DRIO's competition here
Precipio, Inc. (NASDAQ: PRPO)
CEMI vs PRPO Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, PRPO has a market cap of 44M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while PRPO trades at $24.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas PRPO's P/E ratio is -94.96. In terms of profitability, CEMI's ROE is -0.89%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, CEMI is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
CEMI vs MDXH Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MDXH has a market cap of 38.6M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MDXH trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MDXH's P/E ratio is -1.98. In terms of profitability, CEMI's ROE is -0.89%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, CEMI is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
CEMI vs QUCY Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, QUCY has a market cap of 32.6M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while QUCY trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas QUCY's P/E ratio is -0.06. In terms of profitability, CEMI's ROE is -0.89%, compared to QUCY's ROE of -3.26%. Regarding short-term risk, CEMI is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
CEMI vs AKU Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas AKU's P/E ratio is -0.13. In terms of profitability, CEMI's ROE is -0.89%, compared to AKU's ROE of -5.32%. Regarding short-term risk, CEMI is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check AKU's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
CEMI vs ENZ Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ENZ's P/E ratio is -2.24. In terms of profitability, CEMI's ROE is -0.89%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, CEMI is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
CEMI vs PMD Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas PMD's P/E ratio is -5.24. In terms of profitability, CEMI's ROE is -0.89%, compared to PMD's ROE of -0.32%. Regarding short-term risk, CEMI is similarly volatile compared to PMD. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
CEMI vs ME Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ME's P/E ratio is -0.03. In terms of profitability, CEMI's ROE is -0.89%, compared to ME's ROE of -42.03%. Regarding short-term risk, CEMI is similarly volatile compared to ME. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
CEMI vs MYNZ Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, CEMI's ROE is -0.89%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, CEMI is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MYNZ's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
CEMI vs BNGO Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BNGO has a market cap of 13.7M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BNGO trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BNGO's P/E ratio is -0.27. In terms of profitability, CEMI's ROE is -0.89%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, CEMI is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BNGO's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
CEMI vs ADVB Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ADVB has a market cap of 11.7M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ADVB trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ADVB's P/E ratio is -76.64. In terms of profitability, CEMI's ROE is -0.89%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, CEMI is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check ADVB's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
CEMI vs CHEK Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CHEK's P/E ratio is -0.43. In terms of profitability, CEMI's ROE is -0.89%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, CEMI is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check CHEK's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
CEMI vs BNR Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BNR has a market cap of 10.5M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BNR trades at $9.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BNR's P/E ratio is -12.06. In terms of profitability, CEMI's ROE is -0.89%, compared to BNR's ROE of -0.11%. Regarding short-term risk, CEMI is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BNR's competition here
Centogene N.V. (NASDAQ: CNTG)
CEMI vs CNTG Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CNTG's P/E ratio is -0.23. In terms of profitability, CEMI's ROE is -0.89%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, CEMI is similarly volatile compared to CNTG. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check CNTG's competition here
Check-Cap Ltd. Ordinary Share (NASDAQ: MBAI)
CEMI vs MBAI Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MBAI has a market cap of 8.5M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MBAI trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MBAI's P/E ratio is 12.63. In terms of profitability, CEMI's ROE is -0.89%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, CEMI is less volatile compared to MBAI. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MBAI's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
CEMI vs APDN Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas APDN's P/E ratio is -0.10. In terms of profitability, CEMI's ROE is -0.89%, compared to APDN's ROE of -7.23%. Regarding short-term risk, CEMI is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
CEMI vs NDRA Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NDRA has a market cap of 5.8M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NDRA trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NDRA's P/E ratio is -0.58. In terms of profitability, CEMI's ROE is -0.89%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, CEMI is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NDRA's competition here
Invitae Corporation (NYSE: NVTA)
CEMI vs NVTA Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NVTA's P/E ratio is -0.00. In terms of profitability, CEMI's ROE is -0.89%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, CEMI is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
CEMI vs LMDX Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas LMDX's P/E ratio is -0.01. In terms of profitability, CEMI's ROE is -0.89%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, CEMI is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
CEMI vs LMDXW Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, CEMI's ROE is -0.89%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, CEMI is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check LMDXW's competition here
DermTech, Inc. (NASDAQ: DMTK)
CEMI vs DMTK Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas DMTK's P/E ratio is -0.04. In terms of profitability, CEMI's ROE is -0.89%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, CEMI is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
CEMI vs NOTV Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NOTV's P/E ratio is -0.03. In terms of profitability, CEMI's ROE is -0.89%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, CEMI is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
CEMI vs SQL Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas SQL's P/E ratio is -0.40. In terms of profitability, CEMI's ROE is -0.89%, compared to SQL's ROE of +38.02%. Regarding short-term risk, CEMI is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check SQL's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
CEMI vs BIAF Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BIAF has a market cap of 2.5M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BIAF trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BIAF's P/E ratio is -0.05. In terms of profitability, CEMI's ROE is -0.89%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, CEMI is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BIAF's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
CEMI vs AWH Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas AWH's P/E ratio is -0.09. In terms of profitability, CEMI's ROE is -0.89%, compared to AWH's ROE of +1.62%. Regarding short-term risk, CEMI is similarly volatile compared to AWH. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check AWH's competition here
Intelligent Bio Solutions Inc. (NASDAQ: INBS)
CEMI vs INBS Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, INBS has a market cap of 2.1M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while INBS trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas INBS's P/E ratio is -0.38. In terms of profitability, CEMI's ROE is -0.89%, compared to INBS's ROE of -1.74%. Regarding short-term risk, CEMI is less volatile compared to INBS. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check INBS's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
CEMI vs HTGM Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas HTGM's P/E ratio is -0.03. In terms of profitability, CEMI's ROE is -0.89%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, CEMI is similarly volatile compared to HTGM. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
CEMI vs BIOC Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BIOC's P/E ratio is -0.01. In terms of profitability, CEMI's ROE is -0.89%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, CEMI is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
CEMI vs ISPC Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ISPC has a market cap of 336K. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ISPC trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ISPC's P/E ratio is -0.08. In terms of profitability, CEMI's ROE is -0.89%, compared to ISPC's ROE of -4.62%. Regarding short-term risk, CEMI is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
CEMI vs SQLLW Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, CEMI's ROE is -0.89%, compared to SQLLW's ROE of +38.02%. Regarding short-term risk, CEMI is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check SQLLW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
CEMI vs MEUSW Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MEUSW's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, CEMI is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MEUSW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
CEMI vs PRXL Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas PRXL's P/E ratio is 42.97. In terms of profitability, CEMI's ROE is -0.89%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, CEMI is less volatile compared to PRXL. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check PRXL's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
CEMI vs NDRAW Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NDRAW's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, CEMI is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
CEMI vs DHR-PA Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, CEMI's ROE is -0.89%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, CEMI is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check DHR-PA's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
CEMI vs OCDX Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas OCDX's P/E ratio is -42.28. In terms of profitability, CEMI's ROE is -0.89%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, CEMI is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check OCDX's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
CEMI vs BNGOW Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BNGOW's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, CEMI is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
CEMI vs CHEKZ Comparison August 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, CEMI is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check CHEKZ's competition here